Clinical Trial Update: A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ARV-806 evaluating KRAS G12D-mutant advanced solid tumors in adults; Phase 1/2, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ARV-806

Snippet

Sponsor: Arvinas Inc. | Conditions: KRAS G12D Mutation, Advanced Solid Cancer | Phase 1, Phase 2 | Status: RECRUITING